Key Developments For Orchid Cellmark Inc.
Orchid Cellmark Inc. (ORCH.O) (Consolidated Issue listed on NASDAQ Global Market)
Orchid Cellmark, Inc. To Consolidate U.S. Paternity Testing At Ohio Facility
Orchid Cellmark, Inc. announced that a planned consolidation of the Company's East Lansing, Michigan paternity testing operations into its Dayton, Ohio facility. The transfer of the paternity testing operations to the Dayton facility is expected to begin within the next month.
Orchid Cellmark, Inc. Announces $1 Million Worldwide Licensing Agreement To Commercialize Nucleotide Extension Technology
Orchid Cellmark, Inc. announced it has granted a worldwide license to Illumina, Inc. for the commercial development of Orchid's single base nucleotide extension technology for the diagnostic and forensic fields. Under the terms of the license transaction, Orchid receives an upfront fee of $850,000 as well as the potential of an additional $150,000 in contingent payments. Orchid will also collect royalties received by Illumina through any subcontracting arrangements. Additionally, the licensing agreement allows Orchid to purchase certain Illumina product offerings utilizing the patents as a preferred customer. Under the agreement, Orchid Cellmark reserves the rights to use the licensed patents for all fields of use.
Washington State Selects Orchid Cellmark, Inc. As Sole CODIS Supplier
Orchid Cellmark, Inc. announced that the Company has been awarded, as sole supplier, a contract providing convicted offender DNA typing services for the State of Washington, Washington State Patrol (WSP). The award is for a two year contract with the option for three one year renewals. Under the terms of the contract, Orchid Cellmark, Inc. expects to conduct DNA analysis for a backlog of thousands of samples submitted by WSP's CODIS Crime Laboratory (CCL) over the next six to seven months with an estimated value of approximately $875,000.
Orchid Cellmark, Inc. Announces Resignation Of George H. Poste As Chairman-Form 8-K
Orchid Cellmark, Inc. reported in its Form 8-K that on August 25, 2009, George H. Poste, notified that he will not stand for re-election to the Board of Directors at 2009 annual meeting of stockholders to be held on October 7, 2009 and resigned as a Director and as the Chairman of the Company's Board of Directors effective August 25, 2009.
Florida's Department of Revenue Upholds Contract Award To Orchid Cellmark, Inc. For Multi-Year Paternity Testing
Orchid Cellmark, Inc. announced that the State of Florida's Department of Revenue has upheld the contract award to the Company to conduct all publicly-funded paternity testing for the State of Florida. The contract was originally awarded to Orchid Cellmark late last year, but was delayed when Laboratory Corporation of America (LabCorp), a former State of Florida DNA paternity testing provider, protested the award. The award of the entire contract to Orchid Cellmark was upheld by the Department of Revenue based on the findings of the administrative law judge in Florida who presided over a three-day trial in April 2008. The new, multi-year contract begins September 1, 2008 and is extendable for an additional three years beyond its expiration in 2011. Under the terms of the contract, Orchid Cellmark will provide DNA paternity testing services for the Division of Child Support Enforcement of Florida's Department of Revenue throughout the whole state. Orchid Cellmark previously provided DNA testing services for approximately one-third of the State of Florida, while LabCorp serviced the remaining two-thirds of the state.
